Carlos Gomez-Roca

1.9k total citations
4 papers, 150 citations indexed

About

Carlos Gomez-Roca is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carlos Gomez-Roca has authored 4 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Immunology and 1 paper in Molecular Biology. Recurrent topics in Carlos Gomez-Roca's work include Cancer Immunotherapy and Biomarkers (2 papers), Immune cells in cancer (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Carlos Gomez-Roca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (2 papers), Immune cells in cancer (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Carlos Gomez-Roca collaborates with scholars based in France, Germany and Switzerland. Carlos Gomez-Roca's co-authors include Michael A. Cannarile, Christophe Le Tourneau, R D Christen, Winette T.A. van der Graaf, Florian Heil, Carla van Herpen, Tapan K. Nayak, Valérie Méresse, C. Willemien Menke‐van der Houven van Oordt and Dominik Rüttinger and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncotarget.

In The Last Decade

Carlos Gomez-Roca

4 papers receiving 149 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos Gomez-Roca France	3	81	64	58	36	19	4	150
Monika Baehner Switzerland	6	65 0.8×	67 1.0×	70 1.2×	13 0.4×	25 1.3×	8	162
Bryant Harbourne Canada	5	81 1.0×	95 1.5×	77 1.3×	19 0.5×	20 1.1×	6	190
Sophie Léon France	4	64 0.8×	92 1.4×	54 0.9×	21 0.6×	24 1.3×	4	167
Tosei Ohmura Japan	5	87 1.1×	133 2.1×	101 1.7×	24 0.7×	35 1.8×	12	233
Jane Ho Chun Loong China	4	64 0.8×	149 2.3×	58 1.0×	27 0.8×	59 3.1×	5	257
Marina Roy-Luzarraga United Kingdom	5	101 1.2×	116 1.8×	68 1.2×	41 1.1×	24 1.3×	6	227
Catherine A. Eberlein United Kingdom	4	74 0.9×	69 1.1×	27 0.5×	19 0.5×	37 1.9×	4	149
Natalie L. Kingston United States	5	103 1.3×	86 1.3×	64 1.1×	10 0.3×	35 1.8×	6	196
Irati Garmendia Spain	8	98 1.2×	112 1.8×	42 0.7×	24 0.7×	54 2.8×	12	219
Roger Inhorn United States	7	125 1.5×	79 1.2×	72 1.2×	15 0.4×	53 2.8×	9	215

Countries citing papers authored by Carlos Gomez-Roca

Since Specialization

Citations

This map shows the geographic impact of Carlos Gomez-Roca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Gomez-Roca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Gomez-Roca more than expected).

Fields of papers citing papers by Carlos Gomez-Roca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Gomez-Roca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Gomez-Roca. The network helps show where Carlos Gomez-Roca may publish in the future.

Co-authorship network of co-authors of Carlos Gomez-Roca

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Gomez-Roca. A scholar is included among the top collaborators of Carlos Gomez-Roca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Gomez-Roca. Carlos Gomez-Roca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Champiat, Stéphane, Philippe A. Cassier, Nuria Kotecki, et al.. (2023). Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors. Cancer Research. 83(7_Supplement). 2129–2129. 2 indexed citations

2.

Oordt, C. Willemien Menke‐van der Houven van, Carlos Gomez-Roca, Carla van Herpen, et al.. (2016). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. 7(48). 80046–80058. 113 indexed citations

3.

Gomez-Roca, Carlos, Philippe A. Cassier, Antoîne Italiano, et al.. (2015). Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 3005–3005. 28 indexed citations

4.

Cassier, Philippe A., Carlos Gomez-Roca, Antoîne Italiano, et al.. (2014). Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).. Journal of Clinical Oncology. 32(15_suppl). 10504–10504. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact